Lupin Limited, a global pharmaceutical company, has announced the appointment of Dr. Ranjana Pathak as its new Chief Quality Officer. Dr. Pathak will succeed Johnny Mikell, who is retiring from the company after serving as Chief Quality Officer.

Bringing over three decades of industry experience to her new role, Dr. Pathak will lead Lupin's quality and regulatory compliance efforts across its global operations. She joins Lupin from a distinguished career, having previously served as the Global Head for Quality and Pharmacovigilance at Dr. Reddy's. Before this, she held the position of President and Global Head of Quality, Medical Affairs, and Pharmacovigilance at Cipla. 

Additionally, Dr. Pathak has held leadership roles in global quality and compliance at Watson/Actavis and Endo Pharmaceuticals in the US. Her expertise spans across generic and brand medicines, covering various dosage platforms such as injectables, inhalation products, and biologics.

In a statement, Vinita Gupta, CEO, and Nilesh Gupta, MD, of Lupin expressed gratitude to Johnny Mikell for his five years of service to the company and welcomed Dr. Ranjana Pathak to the executive leadership team. “We are delighted to welcome Ranjana to our executive leadership team. Her extensive global experience and proven track record in building and sustaining a strong culture of quality and compliance align with Lupin’s commitment to be best-in-class in delivering quality products to the communities we serve,” they said.